These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 9499331)

  • 1. Epidemiology of oral contraceptives and cardiovascular disease.
    Chasan-Taber L; Stampfer MJ
    Ann Intern Med; 1998 Mar; 128(6):467-77. PubMed ID: 9499331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.
    Mann JI
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):752-7. PubMed ID: 7065056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L; Palmer JR; Sands MI; Grimes D; Bergman U; Daling J; Mills A
    Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States.
    Schwingl PJ; Ory HW; Visness CM
    Am J Obstet Gynecol; 1999 Jan; 180(1 Pt 1):241-9. PubMed ID: 9914611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke.
    Castelli WP
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S349-56. PubMed ID: 10368520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
    Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives.
    Thorogood M; Vessey MP
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):274-81. PubMed ID: 2196799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O
    BMJ; 1993 Apr; 306(6883):956-63. PubMed ID: 8490470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contraceptive choices in women with coagulation disorders.
    Comp PC; Zacur HA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and risks of oral contraceptives.
    Sherif K
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S343-8. PubMed ID: 10368519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.